Merck’s shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.

AstraZeneca (LSE:AZN) recently entered into a collaborative research initiative with IonQ, AWS, and NVIDIA, focused on ...

Astrazeneca unveiled overhaul of its manufacturing and supply operations driven by deep tech and AI at London Tech Week.

UK privately-held T-regulatory (Treg) cell therapies developer Quell Therapeutics today revealed that pharma major ...

AstraZeneca targets $80bn revenue by 2030, driven by oncology and new drugs, but faces patent risks and tough competition.

Merck (MRK) stock is in focus as its Enflonsia RSV shot is cleared for infants in the U.S. in a market led by Sanofi (SNY) ...

The most recent trading session ended with Astrazeneca (AZN) standing at $73.83, reflecting a +1.12% shift from the previouse trading day's closing. This move outpaced the S&P 500's daily gain of 0.55 ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

Merck’s Enflonsia will go up against Sanofi and AstraZeneca’s Beyfortus, which the partners plan to ship out early in the ...

Patent and trademark enforcement has become an important economic tool for entrepreneurs.

The pharmaceutical drug company AstraZeneca filed a lawsuit against the Utah attorney general claiming Utah's new law on ...

The astraszenecaglobal.xyz scam is abusing the real pharmaceutical giant’s name to run a fake investment scheme targeting ...